No Increase in Blood Pressure Assessed With the 24‐h Holter Monitoring in Patients With Episodic Migraine During Early Treatment With Anti‐<scp>CGRP</scp> Monoclonal Antibodies: A Prospective Observational Study (<scp>SAFHYPER</scp>)
Anti-CGRP mAbs did not induce clinically relevant BP increases in the early treatment phase and were associated with improved nocturnal DBP and a favorable shift in dipping profile in patients with EM. These findings suggest the short-term cardiovascular safety of anti-CGRP mAbs, though further studies with larger cohorts and longer follow-up are warranted.
Authors
- Luca Pani (ORCID: https://orcid.org/0000-0001-9273-2839)
- Daria Brovia
- Alberto Boccalini
- Flavia Lo Castro (ORCID: https://orcid.org/0000-0002-8572-3421)
- Luigi Francesco Iannone (ORCID: https://orcid.org/0000-0003-3598-0195)
- Simona Guérzoni (ORCID: https://orcid.org/0000-0001-9589-2782)
- Niccolò Bonini
- Giuseppe Boriani (ORCID: https://orcid.org/0000-0002-9820-4815)
Institutions
- University of Modena and Reggio Emilia (IT)
- University of Miami (US)
- Azienda Ospedaliero-Universitaria di Modena (IT)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1111/ene.70351
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47